CoChat

Warfarin Dosing in Patients With Impaired Kidney Function

Open access
Limdi, Nita A., Limdi, Mohit A., Cavallari, Larisa, Anderson, Aaron M., Crowley, Michael R., Baird, Melissa F., Allon, Michael, Beasley, T. Mark · 2010 · American Journal of Kidney Diseases
Cited by 177

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background Warfarin, a drug primarily metabolized by the cytochrome P450 system, is initiated at similar doses and managed similarly in patients with kidney impairment as in the general medical population. Unfortunately, few data exist to guide dose adjustment in patients with reduced kidney function. Herein we determine the degree of warfarin dose reduction associated with kidney impairment and make recommendations for warfarin dosing. Study Design Cross-sectional analysis. Setting & Participants Chronic warfarin users followed at anticoagulation clinics (n=980); 708 participants from the University of Alabama (UAB) and 272 participants from the University of Chicago (UIC). Predictor No/mild (eGFR≥60ml/min/1.73 m2), moderate (eGFR=30–59ml/min/1.73 m2) and severe (eGFR<30ml/min/1.73 m2) kidney impairment, CYP2C9 and VKORC1 genotype, age, race, gender, body mass, socio-demographic factors, smoking status, alcohol, vitamin K intake, comorbid conditions (e.g. CHF, etc.) and drug interactions (e.g. amiodarone, statins, etc.). Outcome & Measurement Warfarin dose (mg/day) was evaluated using linear regression after adjustment for clinical demographic and genetic factors. Results The prevalence of moderate kidney impairment (31.8% and 27.6%) and severe kidney impairment (8.9% and 6.6%) was similar in the UAB and UIC cohorts. Warfarin dose requirements were significantly lower in patients with moderate and severe kidney impairment compared to those with none/mild kidney impairment in the UAB (p<0.001) and UIC (p<0.001) cohorts. Compared to patients with no/mild kidney impairment, patients with moderate kidney impairment required 9.5% lower doses (p<0.001) and patients with severe kidney impairment required 19% lower doses (p<0.001). Limitations No measurement of warfarin, serum albumin, vitamin K and clotting factor levels, no evaluation of other markers (e.g. cystatin). Conclusion Moderate and severe kidney impairment were associated with a reduction in warfarin dose requirements.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.ajkd.2010.05.023

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Metadata

Authors
Limdi, N. A., Limdi, M. A., Cavallari, L., Anderson, A. M., Crowley, M. R., Baird, M. F., Allon, M., & Beasley, T. M.
Venue
American Journal of Kidney Diseases
Publisher
Elsevier BV
Published
2010-11
Volume
56
Issue
5
Pages
823-831
ISSN
0272-6386 (ISSN-L)
OpenAlex
W2008943938
Cited by
177
References
5
FWCI
11.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Warfarin Dosing in Patients With Impaired Kidney Function. https://app.cochat.ai/papers/10.1053/j.ajkd.2010.05.023
The paper
Limdi, N. A., Limdi, M. A., Cavallari, L., Anderson, A. M., Crowley, M. R., Baird, M. F., Allon, M., & Beasley, T. M. (2010). Warfarin Dosing in Patients With Impaired Kidney Function. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2010.05.023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.